These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 21123772

  • 1. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Sahu AK, Majji AB.
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
    [No Abstract] [Full Text] [Related]

  • 2. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L, PKC-DRS2 Study Group.
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [Abstract] [Full Text] [Related]

  • 3. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 4. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH, MBDL and MBCU Study Groups.
    Invest Ophthalmol Vis Sci; 2013 Mar 11; 54(3):1750-7. PubMed ID: 23404115
    [Abstract] [Full Text] [Related]

  • 5. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC, PKC-DRS and PKC-DRS2 Study Groups.
    Retina; 2011 Nov 11; 31(10):2084-94. PubMed ID: 21862954
    [Abstract] [Full Text] [Related]

  • 6. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP, Mbdv Study Group.
    Retina; 2011 Jun 11; 31(6):1053-9. PubMed ID: 21386766
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Medications for diabetic macular edema].
    Kitano S.
    Nihon Rinsho; 2005 Jun 11; 63 Suppl 6():275-9. PubMed ID: 15999719
    [No Abstract] [Full Text] [Related]

  • 10. Ruboxistaurin for diabetic retinopathy.
    Gardner TW, Antonetti DA.
    Ophthalmology; 2006 Dec 11; 113(12):2135-6. PubMed ID: 17157131
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
    Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE.
    Invest Ophthalmol Vis Sci; 2006 Jan 11; 47(1):86-92. PubMed ID: 16384948
    [Abstract] [Full Text] [Related]

  • 13. Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.
    Gálvez MI.
    Curr Diabetes Rev; 2009 Feb 11; 5(1):14-7. PubMed ID: 19199893
    [Abstract] [Full Text] [Related]

  • 14. [New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].
    Lagrèze WA.
    MMW Fortschr Med; 2003 Apr 03; 145(14):37-8. PubMed ID: 15072277
    [No Abstract] [Full Text] [Related]

  • 15. Update on treatments for diabetic macular edema.
    Fraser-Bell S, Kaines A, Hykin PG.
    Curr Opin Ophthalmol; 2008 May 03; 19(3):185-9. PubMed ID: 18408491
    [Abstract] [Full Text] [Related]

  • 16. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group.
    Diabetes; 2005 Jul 03; 54(7):2188-97. PubMed ID: 15983221
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Retinopathy, a major cause of blindness in the adult diabetic].
    Angioi-Duprez K.
    Soins; 2006 Mar 03; (703 Suppl 1):1S12-5. PubMed ID: 16604810
    [No Abstract] [Full Text] [Related]

  • 19. Molecule of the month. Ruboxistaurin mesilate hydrate.
    Drug News Perspect; 2003 Dec 03; 16(10):691. PubMed ID: 14747848
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.